Cicada HTH presents: Bench to Boardroom Networking Event

Join us at Cicada Healthtech Hub Westmead for Bench to Boardroom, a networking night for researchers and emerging leaders. You’ll hear from people who’ve built careers in start-ups, industry and beyond, and meet others across the health and life sciences community. 🧪 What you'll gain • Real stories of researchers who’ve moved into leadership roles in start-ups, industry, government and the for-purpose sector. • Practical tips on changing how you communicate as you step from team member to leader. • A clearer sense of your own leadership style through an interactive activity. • Candid advice from the panel on commercialisation, executive roles and entrepreneurship. • The chance to put your own career questions to experienced leaders. • New connections across the Westmead health and life sciences community. 🎤 Speakers Include: • Welcome & Opening remarks: Lilly Bojarski, GM, Cicada HealthTech Hub • Keynote: Julia Palmer (Keynote): Relational Strategist and CEO, Relatus • Dr Gisela Mautner: ASX-listed biotech CEO and founder of Mautner Docs, formerly at Noxopharm, MSD, Bayer and Amgen • Joss Morris: Principal Adviser at Joss Morris Advisory • Shane Herbert: Executive and leadership coach, Vistage 🥂 Program at a Glance • 5:00pm: Arrivals, registration and networking • 5:30pm: Welcome and Acknowledgement of Country • 5:45pm: Keynote and interactive leadership activity with Julia Palmer • 6:45pm: Panel discussion and audience Q&A • 7:45pm: Networking drinks and canapés • 8:30pm: Close Capacity is limited. Register now to secure your place at this important gathering of the healthtech and biotech innovation community. Find out more about the Cicada HealthTech Hub The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.